|
1）D’Agati VD, Fogo AB, Bruijn JA, et al. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004; 43: 368-82
|
|
|
|
2）Fries JW, Sandstrom DJ, Meyer TW, et al. Glomerular hypertrophy and epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab Invest. 1989; 60: 205-18
|
|
|
|
|
|
3）Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats. II. Mechanical stress on podocytes as a pathway to sclerosis. Kidney Int. 1992; 42: 148-60
|
|
|
|
|
|
4）D’Agati VD. Podocyte injury in focal segmental glomerulosclerosis: Lessons from animal models(a play in five acts). Kidney Int. 2008; 73: 399-406
|
|
|
|
|
|
5）Detwiler RK, Falk RJ, Hogan SL, et al. Collapsing glomerulopathy: a clinically and pathologically distinct variant of focal segmental glomerulosclerosis. Kidney Int. 1994; 45: 1416-24
|
|
|
|
|
|
6）Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol. 2007; 2: 529-42
|
|
|
|
|
|
7）Nagata M, Horita S, Shu Y, et al. Phenotypic characteristics and cyclin-dependent kinase inhibitors repression in hyperplastic epithelial pathology in idiopathic focal segmental glomerulosclerosis. Lab Invest. 2000; 80: 869-80
|
|
|
|
|
|
8）Smeets B, Kuppe C, Sicking EM, et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol. 2011; 22: 1262-74
|
|
|
|
|
|
9）Suzuki T, Matsusaka T, Nakayama M, et al. Genetic podocyte lineage reveals progressive podocytopenia with parietal cell hyperplasia in a murine model of focal segmental glomerulosclerosis. Am J Pathol. 2009; 174: 1675-82
|
|
|
|
|
|
10）Ueno T, Kobayashi N, Nakayama M, et al. Aberrant Notch1-dependent effects on glomerular parietal epithelial cells promotes collapsing focal segmental glomerulosclerosis with progressive podocyte loss. Kidney Int. 2013; 83: 1065-75
|
|
|
|
|
|
11）Jpelaar DH, Farris AB, Goemaere N, et al. Fidelity and evolution of recurrent FSGS in renal allografts. J Am Soc Nephrol. 2008; 19: 2219-24
|
|
|
|
|
|
12）Choi HJ, Lee BH, Cho HY, et al. Familial focal segmental glomerulosclerosis associated with an ACTN4 mutation and paternal germline mosaicism. Am J Kidney Dis. 2008; 51: 834-8
|
|
|
|
|
|
13）Howie AJ, Brewer DB. The glomerular tip lesion: a previously undescribed type of segmental glomerular abnormality. J Pathol. 1984; 142: 205-20
|
|
|
|
|
|
14）Stokes MB, Markowitz GS, Lin J, et al. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int. 2004; 65: 1690-702
|
|
|
|
|
|
15）Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008; 358: 1129-36
|
|
|
|
|
|
16）Taneda S, Honda K, Yumura W, et al. Histological heterogeneity of glomerular segmental lesions in focal segmental glomerulosclerosis. Int Urol Nephrol. 2012; 44: 183-96
|
|
|
|
|